Literature DB >> 31017805

Tissue-specific dysregulation of mitochondrial respiratory capacity and coupling control in colon-26 tumor-induced cachexia.

Jessica L Halle1, Gabriel S Pena1, Hector G Paez1, Adrianna J Castro1, Harry B Rossiter2,3, Nishant P Visavadiya1, Michael A Whitehurst1, Andy V Khamoui1.   

Abstract

In addition to skeletal muscle dysfunction, cancer cachexia is a systemic disease involving remodeling of nonmuscle organs such as adipose and liver. Impairment of mitochondrial function is associated with multiple chronic diseases. The tissue-specific control of mitochondrial function in cancer cachexia is not well defined. This study determined mitochondrial respiratory capacity and coupling control of skeletal muscle, white adipose tissue (WAT), and liver in colon-26 (C26) tumor-induced cachexia. Tissues were collected from PBS-injected weight-stable mice, C26 weight-stable mice and C26 mice with moderate (10% weight loss) and severe cachexia (20% weight loss). The respiratory control ratio [(RCR) an index of oxidative phosphorylation (OXPHOS) coupling efficiency] was low in WAT during the induction of cachexia because of high nonphosphorylating LEAK respiration. Liver RCR was low in C26 weight-stable and moderately cachexic mice because of reduced OXPHOS. Liver RCR was further reduced with severe cachexia, where Ant2 but not Ucp2 expression was increased. Ant2 was inversely correlated with RCR in the liver (r = -0.547, P < 0.01). Liver cardiolipin increased in moderate and severe cachexia, suggesting this early event may also contribute to mitochondrial uncoupling. Impaired skeletal muscle mitochondrial respiration occurred predominantly in severe cachexia, at complex I. These findings suggest that mitochondrial function is subject to tissue-specific control during cancer cachexia, whereby remodeling in WAT and liver arise early and may contribute to altered energy balance, followed by impaired skeletal muscle respiration. We highlight an under-recognized role of liver and WAT mitochondrial function in cancer cachexia and suggest mitochondrial function of multiple tissues to be therapeutic targets.

Entities:  

Keywords:  OXPHOS; adipose; cancer cachexia; high-resolution respirometry; liver; skeletal muscle atrophy

Year:  2019        PMID: 31017805     DOI: 10.1152/ajpregu.00028.2019

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  17 in total

1.  Methylarginine metabolites are associated with attenuated muscle protein synthesis in cancer-associated muscle wasting.

Authors:  Hawley E Kunz; Jessica M Dorschner; Taylor E Berent; Thomas Meyer; Xuewei Wang; Aminah Jatoi; Rajiv Kumar; Ian R Lanza
Journal:  J Biol Chem       Date:  2020-10-01       Impact factor: 5.157

Review 2.  Muscle alterations in the development and progression of cancer-induced muscle atrophy: a review.

Authors:  Megan E Rosa-Caldwell; Dennis K Fix; Tyrone A Washington; Nicholas P Greene
Journal:  J Appl Physiol (1985)       Date:  2019-11-14

Review 3.  Exercise as a therapy for cancer-induced muscle wasting.

Authors:  Jessica L Halle; Brittany R Counts; James A Carson
Journal:  Sports Med Health Sci       Date:  2020-12-03

4.  Mitochondrial dynamics and quality control are altered in a hepatic cell culture model of cancer cachexia.

Authors:  Nishant P Visavadiya; Gabriel S Pena; Andy V Khamoui
Journal:  Mol Cell Biochem       Date:  2020-08-14       Impact factor: 3.396

5.  Methylarginine metabolites are associated with attenuated muscle protein synthesis in cancer-associated muscle wasting.

Authors:  Hawley E Kunz; Jessica M Dorschner; Taylor E Berent; Thomas Meyer; Xuewei Wang; Aminah Jatoi; Rajiv Kumar; Ian R Lanza
Journal:  J Biol Chem       Date:  2020-12-18       Impact factor: 5.157

6.  Pectoralis major muscle atrophy is associated with mitochondrial energy wasting in cachectic patients with gastrointestinal cancer.

Authors:  Adeline Dolly; Thierry Lecomte; Nicolas Tabchouri; Morgane Caulet; Nicolas Michot; Benjamin Anon; Romain Chautard; Yoann Desvignes; Mehdi Ouaissi; Gaëlle Fromont-Hankard; Jean-François Dumas; Stéphane Servais
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-03-22       Impact factor: 12.063

7.  Inflammation-induced cholestasis in cancer cachexia.

Authors:  Morgane M Thibaut; Martina Sboarina; Martin Roumain; Sarah A Pötgens; Audrey M Neyrinck; Florence Destrée; Justine Gillard; Isabelle A Leclercq; Guillaume Dachy; Jean-Baptiste Demoulin; Anne Tailleux; Sophie Lestavel; Marialetizia Rastelli; Amandine Everard; Patrice D Cani; Paolo E Porporato; Audrey Loumaye; Jean-Paul Thissen; Giulio G Muccioli; Nathalie M Delzenne; Laure B Bindels
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-12-22       Impact factor: 12.910

8.  Distinct glycolytic pathway regulation in liver, tumour and skeletal muscle of mice with cancer cachexia.

Authors:  Nishant P Visavadiya; Harry B Rossiter; Andy V Khamoui
Journal:  Cell Biochem Funct       Date:  2021-06-15       Impact factor: 3.963

Review 9.  Cachexia, a Systemic Disease beyond Muscle Atrophy.

Authors:  Elisabeth Wyart; Laure B Bindels; Erica Mina; Alessio Menga; Serena Stanga; Paolo E Porporato
Journal:  Int J Mol Sci       Date:  2020-11-14       Impact factor: 5.923

10.  Mitochondrial Function and Protein Turnover in the Diaphragm are Altered in LLC Tumor Model of Cancer Cachexia.

Authors:  Megan E Rosa-Caldwell; Conner A Benson; David E Lee; Jacob L Brown; Tyrone A Washington; Nicholas P Greene; Michael P Wiggs
Journal:  Int J Mol Sci       Date:  2020-10-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.